Clinical Trial Update: TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss [Phase 1, Phase 2]

View source ↗

Summary

Early-phase trial investigating TQB3525 in advanced bone sarcomas with PI3KA mutations or PTEN loss; status and results are not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Sarcoma

Drugs mentioned

• TQB3525

Snippet

Sponsor: Peking University People's Hospital | Conditions: Safety Issues, Efficacy, Self | Phase 1, Phase 2 | Status: UNKNOWN